Warrants of Series TO 1

During the period 23rd of August – 13th of September 2018, holders of warrants of series TO 1 can subscribe for shares by exercising their warrants. Each warrant entitles to subscription of one new share for a subscription price of SEK 5.00. Warrants of series TO 1 are traded on Spotlight Stock Market until September 11th 2018 under the ticker “NXTCL TO 1”. Please note that warrants of series TO 1 will expire with no value if the holder does not actively subscribe for shares by September 13th 2018 at the latest, or sells their warrants by September 11th 2018 at the latest.  

Link to Teaser

Link to Subscription form


Financial Calendar 2018

Q1 Report, 2018

31 January, 2018

Q2 Report, 2018

30 April, 2018

Q3 Report, 2018

31 July, 2018

       Annual Report, 2018

31 October, 2018


Financial Calendar 2017

Interim Report, 2017

31 July, 2017

Year End Report, 2017

31 October, 2017

Annual Report, 2018

14 November, 2017

Annual General Meeting, 2017

Conducted December 5, 2017

Sharing Information

Dividends And Transparency


NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development. There is a risk that future cash flows will not exceed the company’s capital requirements and that future AGMs will not decide on future dividends.


Shares in NextCell Pharma AB are traded on Spotlight Markets as per July 2017.

List of 5 largest shareholders as per 2018-03-31

Owners / Shares / Percentage

Diamyd Medical AB* / 1 173 723 / 13.8 

Avanza Pension / 972 170 / 11,43

Anders Essen-Möller** / 546 898 / 6,43

Bertil Lindkvist / 444 833 / 5,23

Göran Ofsen / 380 192 / 4,47

Other Owners / 4 987 581*** / 58,64***

* NextCell’s Board Chairman Anders Essen-Möller owns 16.8% of the shares and 40.1% of the votes in Diamyd Medical AB. ** Anders Essen-Möller is the Board Chairman of NextCell. *** Numbers are close approximations and can deviate slightly form reality

Share price

The current share price is available on Aktietorget.


Corporate Gorvenance


Bo Åsell Öhrlings PricewaterhouseCoopers AB (PwC) Torsgatan 21, 113 97 Stockholm Bo Åsell is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden

Articles Of Association

Nomination Committee

No information available

Incentive Programmes

NextCell Pharma AB currently has no active incentive programmes.


Archived documents from IPO 2017


Spotlight Stock Market

NextCell Pharma AB is listed on the Spotlight Stock Market since July 2017.

Link to Spotlight Stock Market

Link to NextCell’s IR page on Spotlight Stock Market

Contact Karolinska Institutet Science Park Hälsovägen 7, 141 57 Huddinge +46 (0)8 735 55 95